1
|
Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes. Animals (Basel) 2023; 13:ani13030468. [PMID: 36766357 PMCID: PMC9913421 DOI: 10.3390/ani13030468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 01/25/2023] [Accepted: 01/28/2023] [Indexed: 02/02/2023] Open
Abstract
Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic.
Collapse
|
2
|
Zhang J, Gao M, Niu Y, Sun J. From DNMT1 degrader to ferroptosis promoter: Drug repositioning of 6-Thioguanine as a ferroptosis inducer in gastric cancer. Biochem Biophys Res Commun 2022; 603:75-81. [DOI: 10.1016/j.bbrc.2022.03.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 03/05/2022] [Indexed: 02/09/2023]
|
3
|
Wang S, Yang X, Wang W, Zhang Y, Li T, Zhao L, Bao Y, Meng X. Interpretation of the absorbed constituents and pharmacological effect of Spica Schizonepetae extract on non-small cell lung cancer. PLoS One 2021; 16:e0248700. [PMID: 33730076 PMCID: PMC7968677 DOI: 10.1371/journal.pone.0248700] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Accepted: 03/03/2021] [Indexed: 12/09/2022] Open
Abstract
As a traditional Chinese medicine (TCM) with a usage history of over 2,000 years in China, Spica Schizonepetae possesses definite clinical activity in the treatment of non-small cell lung cancer (NSCLC). However, its active ingredients and mechanism of action remain unclear at present. The further exploration of its active components and underlying mechanism will provide a basis for the development of candidate anti-tumor drugs. Our previous study explored the chemical constituents of Spica Schizonepetae extract (SSE). On this basis, molecular networking technology was applied in analyzing the QTOF-MS/MS data of rat plasma after intragastric administration of SSE using the GNPS database platform. A total of 26 components were found, including 9 proterotype components and 17 metabolites, which revealed the potential active ingredients of SSE. Later, the Lewis lung cancer mouse model was established, and the inhibition rate and histopathological sections were used as the indicators to investigate the anti-tumor effect of SSE, whereas the body weight, survival rate, thymus index and spleen index served as the indicators to explore the pharmacological effects of SSE on improving mouse immunity. The results showed that SSE had comparable anti-tumor efficacy to cisplatin, which enhanced the immunity, improved the quality of life, and extended the survival time of lung cancer mice. Furthermore, human A549 lung tumor cells were selected to explore the mechanism of SSE in treating NSCLC based on cell metabonomics. After data mining by the MPP software, 23 differential endogenous metabolites were identified between SSE and tumor groups. Moreover, results of pathway enrichment analysis using the MetaboAnalyst 4.0 software indicated that these metabolites were mainly enriched in four metabolic pathways (p < 0.1). By adopting the network pharmacology method, the metabolic pathways discovered by cell metabolomics were verified against the ChEMBL, STITCH, UniProt and TCGA databases, and differences in the underlying mechanism between cells and humans were found. It was proved that SSE affected the metabolism of purine, arachidonic acid and histidine to exert the anti-tumor efficacy. Furthermore, the multi-target, multi-pathway, and immunoenhancement mechanism of SSE in anti-tumor treatment was revealed, which provided a scientific basis for new drug development and the rational application of Spica Schizonepetae in clinic.
Collapse
Affiliation(s)
- Shuai Wang
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
| | - Xinxin Yang
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
| | - Wei Wang
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
| | - Yunkun Zhang
- The Second Affiliated Hospital of Dalian Medical University, Dalian, China
| | - Tianjiao Li
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
| | - Lin Zhao
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
| | - Yongrui Bao
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
- * E-mail: (YB); (XM)
| | - Xiansheng Meng
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
- * E-mail: (YB); (XM)
| |
Collapse
|
4
|
Xavier PLP, Müller S, Fukumasu H. Epigenetic Mechanisms in Canine Cancer. Front Oncol 2020; 10:591843. [PMID: 33194754 PMCID: PMC7646326 DOI: 10.3389/fonc.2020.591843] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 10/05/2020] [Indexed: 01/18/2023] Open
Abstract
A plethora of data has highlighted the role of epigenetics in the development of cancer. Initiation and progression of different cancer types are associated with a variety of changes of epigenetic mechanisms, including aberrant DNA methylation, histone modifications, and miRNA expression. At the same time, advances in the available epigenetic tools allow to investigate and reverse these epigenetic changes and form the basis for the development of anticancer drugs in human oncology. Although human and canine cancer shares several common features, only recently that studies emerged investigating the epigenetic landscape in canine cancer and applying epigenetic modulators to canine cancer. This review focuses on the existing studies involving epigenetic changes in different types of canine cancer and the use of small-molecule inhibitors in canine cancer cells.
Collapse
Affiliation(s)
- Pedro Luiz Porfirio Xavier
- Laboratory of Comparative and Translational Oncology (LOCT), Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of Sao Paulo, Pirassununga, Brazil
| | - Susanne Müller
- Structural Genomics Consortium and Institute of Pharmaceutical Chemistry, Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Heidge Fukumasu
- Laboratory of Comparative and Translational Oncology (LOCT), Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of Sao Paulo, Pirassununga, Brazil
| |
Collapse
|
5
|
Parachini-Winter C, Bracha S, Ramsey SA, Yang L, Ho E, Leeper HJ, Curran KM. Prospective evaluation of the lymph node proteome in dogs with multicentric lymphoma supplemented with sulforaphane. J Vet Intern Med 2020; 34:2036-2047. [PMID: 32926463 PMCID: PMC7517837 DOI: 10.1111/jvim.15898] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 08/18/2020] [Accepted: 08/19/2020] [Indexed: 12/21/2022] Open
Abstract
Background Lymphoma (LSA) is a common malignancy in dogs. Epigenetic changes are linked to LSA pathogenesis and poor prognosis in humans, and LSA pathogenesis in dogs. Sulforaphane (SFN), an epigenetic‐targeting compound, has recently gained interest in relation to cancer prevention and therapy. Objective Examine the impact of oral supplementation with SFN on the lymph node proteome of dogs with multicentric LSA. Animals Seven client‐owned dogs with multicentric LSA. Methods Prospective, nonrandomized, noncontrolled study in treatment‐naïve dogs with intermediate or large cell multicentric LSA. Lymph node cell aspirates were obtained before and after 7 days of oral supplementation with SFN, and analyzed via label‐free mass spectrometry, immunoblots, and Gene Set Enrichment Analysis. Results There was no clinical response and no adverse events attributed to SFN. For individual dogs, the expression of up to 650 proteins changed by at least 2‐fold (range, 2‐100) after supplementation with SFN. When all dogs where analyzed together, 14 proteins were significantly downregulated, and 10 proteins were significantly upregulated after supplementation with SFN (P < .05). Proteins and gene sets impacted by SFN were commonly involved in immunity, response to oxidative stress, gene transcription, apoptosis, protein transport, maturation and ubiquitination. Conclusions and Clinical Importance Sulforaphane is associated with major changes in the proteome of neoplastic lymphocytes in dogs.
Collapse
Affiliation(s)
- Cyril Parachini-Winter
- Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA
| | - Shay Bracha
- Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA
| | - Stephen A Ramsey
- Department of Biomedical Sciences, School of Electrical Engineering and Computer Science, Oregon State University, Corvallis, Oregon, USA
| | - Liping Yang
- Department of Chemistry, College of Science, Oregon State University, Corvallis, Oregon, USA
| | - Emily Ho
- Linus Pauling Institute and College of Public Health and Human Sciences, Oregon State University, Corvallis, Oregon, USA
| | - Haley J Leeper
- Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA
| | - Kaitlin M Curran
- Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA
| |
Collapse
|
6
|
Giannuzzi D, Giudice L, Marconato L, Ferraresso S, Giugno R, Bertoni F, Aresu L. Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog. Vet Comp Oncol 2020; 18:645-655. [PMID: 32154977 DOI: 10.1111/vco.12588] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 02/10/2020] [Accepted: 03/05/2020] [Indexed: 12/17/2022]
Abstract
Marginal zone lymphoma (MZL) and follicular lymphoma (FL) are classified as indolent B-cell lymphomas in dogs. Aside from the clinical and histopathological similarities with the human counterpart, the molecular pathogenesis remains unclear. We integrated transcriptome, genome-wide DNA methylation and copy number aberration analysis to provide insights on the pathogenesis of canine MZL (n = 5) and FL (n = 7), also comparing them with diffuse large B-cell lymphoma (DLBCL). Transcriptome profiling highlighted the presence of similar biological processes affecting both histotypes, including BCR and TLR signalling pathways. However, FLs showed an enrichment of E2F targets, whereas MZLs were characterized by MYC-driven transcriptional activation signatures. FLs showed a distinctive loss on chr1 containing CEACAM23 and 24, conversely MZLs presented multiple recurrent gains on chr13, where MYC is located. The distribution of methylation peaks was similar between the two histotypes. Integrating data from the three omics, FLs resulted clearly separated from MZLs and DLBCL dataset. MZLs showed the enrichment of FoxM1 network and TLR associated TICAM1-dependent IRFs activation pathway. However, no specific signatures differentiated MZLs from DLBCLs. In conclusion, our study presents the first comprehensive analysis of molecular and epigenetic pathogenesis of canine FL and MZL.
Collapse
Affiliation(s)
- Diana Giannuzzi
- Department of Comparative Biomedicine and Food Science, University of Padua, Padua, Italy
| | - Luca Giudice
- Department of Computer Science, University of Verona, Verona, Italy
| | - Laura Marconato
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| | - Serena Ferraresso
- Department of Comparative Biomedicine and Food Science, University of Padua, Padua, Italy
| | - Rosalba Giugno
- Department of Computer Science, University of Verona, Verona, Italy
| | - Francesco Bertoni
- Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland
| | - Luca Aresu
- Department of Veterinary Science, University of Turin, Turin, Italy
| |
Collapse
|
7
|
Rajashekaraiah R, Kumar PR, Prakash N, Rao GS, Devi VR, Metta M, Narayanaswamy HD, Swamy MN, Satyanarayan K, Rao S, Rathnamma D, Sahadev A, Sunilchandra U, Santhosh CR, Dhanalakshmi H, Kumar SN, Ruban SW, Kalmath GP, Gomes AR, Kumar KRA, Govindappa PK. Anticancer efficacy of 6-thioguanine loaded chitosan nanoparticles with or without curcumin. Int J Biol Macromol 2020; 148:704-714. [PMID: 31954127 DOI: 10.1016/j.ijbiomac.2020.01.117] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Revised: 01/12/2020] [Accepted: 01/12/2020] [Indexed: 12/14/2022]
Abstract
6-Thioguanine encapsulated chitosan nanoparticles (6-TG-CNPs) has formulated by the ionic-gelation method. Morphologically, the 6-TG-CNPs were spherical and showed mean size, PDI, zeta potential, and entrapment efficiency of 261.63 ± 6.01 nm, 0.34 ± 0.10, +15.97 ± 0.46 mV and 44.27%, respectively. The IR spectra confirmed the 6-TG complex with chitosan. The in vitro drug release profile of 6-TG-CNPs revealed an increase in sustained-release (91.40 ± 1.08% at 48 h) at pH 4.8 compared to less sustained-release (73.96 ± 1.12% at 48 h) at pH 7.4. The MTT assay was conducted on MCF-7 and PA-1 cell lines at 48 h incubation to determine % cell viability. The IC50 values of 6-TG, 6-TG-CNPs, and curcumin for MCF-7 were 23.09, 17.82, and 15.73 μM, respectively. Likewise, IC50 values of 6-TG, 6-TG-CNPs, and curcumin for PA-1 were 5.81, 3.92, and 12.89 μM, respectively. A combination of 6-TG-CNPs (IC25) with curcumin (IC25) on PA-1 and MCF-7 showed % cell viability of 43.67 ± 0.02 and 49.77 ± 0.05, respectively. The in vitro cytotoxicity potential in terms of % cell viability, early apoptosis, G2/M phase arrest, and DNA demethylating activity of 6-TG-CNPs alone and combination with curcumin proved to be more effective than that of 6-TG on PA-1 cells.
Collapse
Affiliation(s)
- Rashmi Rajashekaraiah
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India.
| | - P Ravi Kumar
- NTR College of Veterinary Science, Sri Venkateswara Veterinary University, Gannavaram 521102, Andhra Pradesh, India
| | - N Prakash
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - G Srinivasa Rao
- NTR College of Veterinary Science, Sri Venkateswara Veterinary University, Gannavaram 521102, Andhra Pradesh, India
| | - V Rama Devi
- NTR College of Veterinary Science, Sri Venkateswara Veterinary University, Gannavaram 521102, Andhra Pradesh, India
| | - M Metta
- NTR College of Veterinary Science, Sri Venkateswara Veterinary University, Gannavaram 521102, Andhra Pradesh, India
| | - H D Narayanaswamy
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - M Narayana Swamy
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - K Satyanarayan
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - Suguna Rao
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - D Rathnamma
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - A Sahadev
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - U Sunilchandra
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - C R Santhosh
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - H Dhanalakshmi
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - S Naveen Kumar
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - S Wilfred Ruban
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - G P Kalmath
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - A R Gomes
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - K R Anjan Kumar
- Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar 585401, Karnataka, India
| | - Prem Kumar Govindappa
- Department of Orthopaedics and Rehabilitation, Centre for Orthopaedic Research and Translational Science (CORTS), College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA
| |
Collapse
|
8
|
Ribeiro ML, Reyes-Garau D, Armengol M, Fernández-Serrano M, Roué G. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Front Genet 2019; 10:986. [PMID: 31681423 PMCID: PMC6807552 DOI: 10.3389/fgene.2019.00986] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Accepted: 09/17/2019] [Indexed: 12/13/2022] Open
Abstract
In the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte compartment. However, most of these entities remain incurable and current treatments are associated with variable efficacy, several adverse events, and frequent relapses. Thus, new diagnostic paradigms and novel therapeutic options are required to improve the prognosis of patients with B-NHL. With the recent deciphering of the mutational landscapes of B-cell disorders by high-throughput sequencing, it came out that different epigenetic deregulations might drive and/or promote B lymphomagenesis. Consistently, over the last decade, numerous epigenetic drugs (or epidrugs) have emerged in the clinical management of B-NHL patients. In this review, we will present an overview of the most relevant epidrugs tested and/or used so far for the treatment of different subtypes of B-NHL, from first-generation epigenetic therapies like histone acetyl transferases (HDACs) or DNA-methyl transferases (DNMTs) inhibitors to new agents showing selectivity for proteins that are mutated, translocated, and/or overexpressed in these diseases, including EZH2, BET, and PRMT. We will dissect the mechanisms of action of these epigenetic inhibitors, as well as the molecular processes underlying their lack of efficacy in refractory patients. This review will also provide a summary of the latest strategies being employed in preclinical and clinical settings, and will point out the most promising lines of investigation in the field.
Collapse
Affiliation(s)
- Marcelo L. Ribeiro
- Laboratory of Experimental Hematology, Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain
- Laboratory of Immunopharmacology and Molecular Biology, Sao Francisco University Medical School, Braganca Paulista, São Paulo, Brazil
| | - Diana Reyes-Garau
- Laboratory of Experimental Hematology, Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain
| | - Marc Armengol
- Laboratory of Experimental Hematology, Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain
| | - Miranda Fernández-Serrano
- Laboratory of Experimental Hematology, Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain
| | - Gaël Roué
- Laboratory of Experimental Hematology, Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain
| |
Collapse
|
9
|
Da Ros S, Aresu L, Ferraresso S, Zorzan E, Gaudio E, Bertoni F, Dacasto M, Giantin M. Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach. PLoS One 2018; 13:e0208709. [PMID: 30533020 PMCID: PMC6289462 DOI: 10.1371/journal.pone.0208709] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Accepted: 11/21/2018] [Indexed: 01/26/2023] Open
MESH Headings
- Animals
- Cell Line, Tumor
- Dog Diseases/genetics
- Dog Diseases/metabolism
- Dogs
- Epigenesis, Genetic/drug effects
- Gene Expression Regulation, Neoplastic/drug effects
- Gene Expression Regulation, Neoplastic/physiology
- Histone Deacetylase Inhibitors/pharmacology
- Lymph Nodes
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/metabolism
- Lymphoma, Large B-Cell, Diffuse/veterinary
- Promoter Regions, Genetic
- RNA, Messenger/metabolism
Collapse
Affiliation(s)
- Silvia Da Ros
- Department of Comparative Biomedicine and Food Science, University of Padova, Padova, Italy
| | - Luca Aresu
- Department of Veterinary Sciences, University of Turin, Turin, Italy
| | - Serena Ferraresso
- Department of Comparative Biomedicine and Food Science, University of Padova, Padova, Italy
| | - Eleonora Zorzan
- Department of Comparative Biomedicine and Food Science, University of Padova, Padova, Italy
| | - Eugenio Gaudio
- Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
| | - Francesco Bertoni
- Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Mauro Dacasto
- Department of Comparative Biomedicine and Food Science, University of Padova, Padova, Italy
| | - Mery Giantin
- Department of Comparative Biomedicine and Food Science, University of Padova, Padova, Italy
- * E-mail:
| |
Collapse
|
10
|
Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic. Pharmacol Ther 2018; 188:45-79. [DOI: 10.1016/j.pharmthera.2018.02.006] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
11
|
Anderson SJ, Feye KM, Schmidt-McCormack GR, Malovic E, Mlynarczyk GSA, Izbicki P, Arnold LF, Jefferson MA, de la Rosa BM, Wehrman RF, Luna KC, Hu HZ, Kondru NC, Kleinhenz MD, Smith JS, Manne S, Putra MR, Choudhary S, Massey N, Luo D, Berg CA, Acharya S, Sharma S, Kanuri SH, Lange JK, Carlson SA. Off-Target drug effects resulting in altered gene expression events with epigenetic and "Quasi-Epigenetic" origins. Pharmacol Res 2016; 107:229-233. [PMID: 27025785 DOI: 10.1016/j.phrs.2016.03.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Revised: 03/23/2016] [Accepted: 03/24/2016] [Indexed: 12/16/2022]
Abstract
This review synthesizes examples of pharmacological agents who have off-target effects of an epigenetic nature. We expand upon the paradigm of epigenetics to include "quasi-epigenetic" mechanisms. Quasi-epigenetics includes mechanisms of drugs acting upstream of epigenetic machinery or may themselves impact transcription factor regulation on a more global scale. We explore these avenues with four examples of conventional pharmaceuticals and their unintended, but not necessarily adverse, biological effects. The quasi-epigenetic drugs identified in this review include the use of beta-lactam antibiotics to alter glutamate receptor activity and the action of cyclosporine on multiple transcription factors. In addition, we report on more canonical epigenome changes associated with pharmacological agents such as lithium impacting autophagy of aberrant proteins, and opioid drugs whose chronic use increases the expression of genes associated with addictive phenotypes. By expanding our appreciation of transcriptomic regulation and the effects these drugs have on the epigenome, it is possible to enhance therapeutic applications by exploiting off-target effects and even repurposing established pharmaceuticals. That is, exploration of "pharmacoepigenetic" mechanisms can expand the breadth of the useful activity of a drug beyond the traditional drug targets such as receptors and enzymes.
Collapse
Affiliation(s)
- Stephen J Anderson
- Department of Psychology, Iowa State University College of Liberal Arts and Sciences, Ames, IA 50011, United States; Neuroscience Interdepartmental Program, Iowa State University, Ames, IA 50011, United States
| | - Kristina M Feye
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Garrett R Schmidt-McCormack
- Neuroscience Interdepartmental Program, Iowa State University, Ames, IA 50011, United States; Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Emir Malovic
- Neuroscience Interdepartmental Program, Iowa State University, Ames, IA 50011, United States
| | - Gregory S A Mlynarczyk
- Neuroscience Interdepartmental Program, Iowa State University, Ames, IA 50011, United States; Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Patricia Izbicki
- Neuroscience Interdepartmental Program, Iowa State University, Ames, IA 50011, United States
| | - Larissa F Arnold
- Department of Psychology, Iowa State University College of Liberal Arts and Sciences, Ames, IA 50011, United States; Neuroscience Interdepartmental Program, Iowa State University, Ames, IA 50011, United States
| | - Matthew A Jefferson
- Department of Kinesiology, Iowa State University College of Liberal Arts and Sciences, Ames, IA 50011, United States
| | - Bierlein M de la Rosa
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Rita F Wehrman
- Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - K C Luna
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Hilary Z Hu
- Neuroscience Interdepartmental Program, Iowa State University, Ames, IA 50011, United States
| | - Naveen C Kondru
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Michael D Kleinhenz
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Joe S Smith
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Sireesha Manne
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Marson R Putra
- Neuroscience Interdepartmental Program, Iowa State University, Ames, IA 50011, United States
| | - Shivani Choudhary
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Nyzil Massey
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Diou Luo
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Carrie A Berg
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Sreemoyee Acharya
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Shaunik Sharma
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Sri Harsha Kanuri
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States
| | - Jennifer K Lange
- Department of Kinesiology, Iowa State University College of Liberal Arts and Sciences, Ames, IA 50011, United States
| | - Steve A Carlson
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA 50011, United States.
| |
Collapse
|
12
|
Xi Q, Gao N, Yang Y, Ye W, Zhang B, Wu J, Jiang G, Zhang X. Anticancer drugs induce hypomethylation of the acetylcholinesterase promoter via a phosphorylated-p38-DNMT1-AChE pathway in apoptotic hepatocellular carcinoma cells. Int J Biochem Cell Biol 2015; 68:21-32. [DOI: 10.1016/j.biocel.2015.08.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Revised: 08/17/2015] [Accepted: 08/17/2015] [Indexed: 10/23/2022]
|
13
|
Fulkerson CM, Dhawan D, Jones DR, Marquez VE, Jones PA, Wang Z, Wu Q, Klaunig JE, Fourez LM, Bonney PL, Knapp DW. Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs. Vet Comp Oncol 2015; 15:226-236. [PMID: 26178438 DOI: 10.1111/vco.12159] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2014] [Revised: 05/07/2015] [Accepted: 05/07/2015] [Indexed: 12/31/2022]
Abstract
The purpose of this study was to determine the plasma pharmacokinetics (PK) and toxicity of zebularine, an oral cytidine analog with demethylating activity, in dogs. Plasma zebularine concentrations were determined by HPLC-MS/MS following an oral zebularine dose of 8 or 4 mg kg-1 . Plasma zebularine clearance was constant. Mean maximum concentration (Cmax ) was 23 ± 4.8 and 8.6 ± 1.4 µM following 8 and 4 mg kg-1 , respectively. Mean half-life was 5.7 ± 0.84 and 7.1 ± 2.1 following 8 and 4 mg kg-1 , respectively. A single 8 mg kg-1 dose was well tolerated. Daily 4 mg kg-1 treatment in three laboratory dogs resulted in grade 4 neutropenia (n = 3), grade 1 anorexia (n = 2) and grade 1 or 2 dermatologic changes (n = 2). All adverse events resolved with supportive care. A 4 mg kg-1 dose every 21 days was well tolerated. A follow-up dose escalation study is in progress with a lower starting dose.
Collapse
Affiliation(s)
- C M Fulkerson
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA
| | - D Dhawan
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA
| | - D R Jones
- Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - V E Marquez
- Center for Cancer Research, Chemical Biology Laboratory, National Cancer Institute, Frederick, MD, USA
| | - P A Jones
- Van Adel Research Institute, Grand Rapids, MI, USA
| | - Z Wang
- Department of Environmental Health, School of Public Health, Indiana University, Bloomington, IN, USA
| | - Q Wu
- Department of Environmental Health, School of Public Health, Indiana University, Bloomington, IN, USA
| | - J E Klaunig
- Department of Environmental Health, School of Public Health, Indiana University, Bloomington, IN, USA
| | - L M Fourez
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA
| | - P L Bonney
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA
| | - D W Knapp
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA.,Purdue University Center for Cancer Research, West Lafayette, IN, USA
| |
Collapse
|